GAMMA-2, IFI53, IFP53, WRS, WARS, TrpRS, hWRS, EC=6.1.1.2, Tryptophanyl-tRNA synthetase, INF-induced protein 53, Tryptophan--tRNA ligase, GAMMA-2.
GAMMA-2, IFI53, IFP53, WRS, WARS, TrpRS, hWRS, EC=6.1.1.2, Tryptophanyl-tRNA synthetase, INF-induced protein 53, Tryptophan--tRNA ligase, GAMMA-2.
TrpRS belongs to the family of aminoacyl-tRNA synthetases (ARSs), which are responsible for the accurate pairing of amino acids with their respective tRNAs. This enzyme ensures that tryptophan is correctly incorporated into the growing polypeptide chain during protein synthesis. The reaction involves the formation of tryptophanyl-AMP from tryptophan and ATP, followed by the transfer of tryptophan to tRNA^Trp .
Beyond its canonical role in protein synthesis, TrpRS has been implicated in various physiological and pathological processes. It has been shown to play roles in immune response, angiogenesis, and apoptosis. For instance, TrpRS expression is upregulated by interferon-gamma (IFN-γ), highlighting its involvement in immune regulation .
TrpRS has garnered attention as a potential biomarker and therapeutic target in several diseases. It has been studied as a synovial biomarker for diagnosing septic arthritis, demonstrating high specificity and sensitivity in distinguishing septic arthritis from other inflammatory conditions . Additionally, TrpRS is being explored for its potential roles in cancer, autoimmune diseases, and neurodegenerative disorders .
Human recombinant TrpRS is produced through recombinant DNA technology, allowing for the large-scale production of this enzyme for research and therapeutic purposes. Recombinant TrpRS retains the functional properties of the native enzyme and is used in various biochemical and clinical studies to understand its roles and develop potential therapeutic interventions.